Obseva (NASDAQ:OBSV) and VERONA PHARMA P/S (NASDAQ:VRNA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.
This is a summary of recent ratings and recommmendations for Obseva and VERONA PHARMA P/S, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|VERONA PHARMA P/S||0||0||3||0||3.00|
Volatility & Risk
Obseva has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, VERONA PHARMA P/S has a beta of -1, suggesting that its stock price is 200% less volatile than the S&P 500.
Valuation & Earnings
This table compares Obseva and VERONA PHARMA P/S’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|VERONA PHARMA P/S||N/A||N/A||-$26.56 million||($2.02)||-2.44|
Obseva is trading at a lower price-to-earnings ratio than VERONA PHARMA P/S, indicating that it is currently the more affordable of the two stocks.
This table compares Obseva and VERONA PHARMA P/S’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|VERONA PHARMA P/S||N/A||-15.56%||-13.26%|
Insider and Institutional Ownership
63.6% of Obseva shares are held by institutional investors. Comparatively, 56.1% of VERONA PHARMA P/S shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
VERONA PHARMA P/S beats Obseva on 5 of the 9 factors compared between the two stocks.
Obseva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.
VERONA PHARMA P/S Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.